Author Archives: Sara Agee Le

March 9, 2020
Press Release

The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics, a clinical stage biotech company, announced today a research collaboration to launch up to 13 small molecule programs […]

Read Article
September 27, 2019
In The News

Angus Liu of FierceBiotech reports on new research on Miro1 and implications for Parkinson’s disease.

Read Article
September 26, 2019
In The News

Science Daily reports on a recent publication by researchers at Stanford, Mayo Clinic, and Atomwise.

Read Article
September 12, 2019
In The News

Genetic Engineering & Biotechnology News (GEN) report on a new partnership between Hansoh Pharma and Atomwise.

Read Article
September 11, 2019
Press Release

Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.

Read Article
September 11, 2019
Press Release

Hansoh Pharmaceutical Group Company Limited, a leading biopharmaceutical company in China, and Atomwise, Inc., the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.

Read Article